Predictive Oncology Inc. (POAI)
NASDAQ: POAI
· Real-Time Price · USD
1.15
0.05 (4.55%)
At close: May 01, 2025, 3:59 PM
4.55% (1D)
| Bid | 1.12 |
| Market Cap | 10.27M |
| Revenue (ttm) | 1.66M |
| Net Income (ttm) | -12.66M |
| EPS (ttm) | -1.99 |
| PE Ratio (ttm) | -0.58 |
| Forward PE | 13.75 |
| Analyst | n/a |
| Ask | 1.2 |
| Volume | 128,134 |
| Avg. Volume (20D) | 2,863,001 |
| Open | 1.10 |
| Previous Close | 1.10 |
| Day's Range | 1.07 - 1.23 |
| 52-Week Range | 0.55 - 3.06 |
| Beta | 1.11 |
About POAI
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery usi...
Industry Medical - Instruments & Supplies
Sector Healthcare
IPO Date May 3, 2010
Employees 23
Stock Exchange NASDAQ
Ticker Symbol POAI
3 weeks ago
-2.19%
Renovaro and Predictive Oncology shares are tradin...
Unlock content with
Pro Subscription
1 month ago
+50.89%
Predictive Oncology shares are trading higher after the company announced it developed predictive models from 21 compounds from the Natural Products Discovery Core at the University of Michigan Life Sciences Institute.
